If you were spending upwards of $2.6 billion and 12 years on a product that would ultimately fail, wouldn’t you rather know sooner than later? Cut your losses after year 3 and refocus your resources on the next promising idea?
That’s the position in which pharmaceutical companies find themselves. In fact, it’s their business model. The resources needed to take a drug treatment from concept to reality are extraordinary. And if a treatment is not going to work, the researchers need to know. Now.
To learn more about meeting the promises of cryo-EM, download our free white paper. You’ll gain insights on:
A typical cryo-EM workflow and the potential for backlogs
Utilization conflict and how to minimize investment
How Cray’s expertise can net a 60% speed advantage
With our 45 years of experience handling data-centric workflows, Cray’s solutions are pre-configured to speed time to innovation, handle today’s workloads, and scale to meet the data demands of tomorrow.
Explore related resources: